STI571 reduces NER activity in BCR/ABL-expressing cells. Sliwinski, T., Czechowska, A., Szemraj, J., Morawiec, Z., Skorski, T., & Blasiak, J. Mutation Research, 654(2):162–167, July, 2008. doi abstract bibtex Nucleotide-excision repair (NER) is the most versatile mechanism of DNA repair, recognizing and dealing with a variety of helix-distorting lesions, such as the UV-induced photoproducts cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) photoproducts. We investigated the influence of an anticancer drug, STI571, on the efficacy of NER in removing UV-induced DNA damage. STI571 is used mostly in the treatment of chronic myeloid leukemia and inhibits activity of the BCR/ABL oncogenic tyrosine kinase, which is a hallmark of this disease. NER activity was examined in the BCR/ABL-expressing cell lines K562 and BV173 of myeloid and lymphoid origin, respectively, as well as in CCRF-CEM cells, which do not express BCR/ABL. A murine myeloid parental 32D cell line and its counterpart transfected with the BCR/ABL gene were also tested. NER activity was assessed in the cell extracts by use of an UV-irradiated plasmid as a substrate and by a modified single-cell gel electrophoresis (comet) assay on UV-treated nucleoids. Additionally, quantitative PCR was performed to evaluate the efficacy of the removal of UV-induced lesions from the p53 gene by intact cells. Results obtained from these experiments indicate that STI571 decreases the efficacy of NER in leukemic cells expressing BCR/ABL. Therefore, STI571 may overcome the drug resistance associated with increased DNA repair in BCR/ABL-positive leukemias.
@article{sliwinski_sti571_2008,
title = {{STI571} reduces {NER} activity in {BCR}/{ABL}-expressing cells},
volume = {654},
issn = {0027-5107},
doi = {10.1016/j.mrgentox.2008.06.002},
abstract = {Nucleotide-excision repair (NER) is the most versatile mechanism of DNA repair, recognizing and dealing with a variety of helix-distorting lesions, such as the UV-induced photoproducts cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) photoproducts. We investigated the influence of an anticancer drug, STI571, on the efficacy of NER in removing UV-induced DNA damage. STI571 is used mostly in the treatment of chronic myeloid leukemia and inhibits activity of the BCR/ABL oncogenic tyrosine kinase, which is a hallmark of this disease. NER activity was examined in the BCR/ABL-expressing cell lines K562 and BV173 of myeloid and lymphoid origin, respectively, as well as in CCRF-CEM cells, which do not express BCR/ABL. A murine myeloid parental 32D cell line and its counterpart transfected with the BCR/ABL gene were also tested. NER activity was assessed in the cell extracts by use of an UV-irradiated plasmid as a substrate and by a modified single-cell gel electrophoresis (comet) assay on UV-treated nucleoids. Additionally, quantitative PCR was performed to evaluate the efficacy of the removal of UV-induced lesions from the p53 gene by intact cells. Results obtained from these experiments indicate that STI571 decreases the efficacy of NER in leukemic cells expressing BCR/ABL. Therefore, STI571 may overcome the drug resistance associated with increased DNA repair in BCR/ABL-positive leukemias.},
language = {eng},
number = {2},
journal = {Mutation Research},
author = {Sliwinski, Tomasz and Czechowska, Agnieszka and Szemraj, Janusz and Morawiec, Zbigniew and Skorski, Tomasz and Blasiak, Janusz},
month = jul,
year = {2008},
pmid = {18602021},
keywords = {Animals, Benzamides, Cell Line, Tumor, Cell Survival, DNA Repair, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Piperazines, Polymerase Chain Reaction, Pyrimidines, comet assay},
pages = {162--167},
}
Downloads: 0
{"_id":"ruSGF53d4XFkWaQHz","bibbaseid":"sliwinski-czechowska-szemraj-morawiec-skorski-blasiak-sti571reducesneractivityinbcrablexpressingcells-2008","author_short":["Sliwinski, T.","Czechowska, A.","Szemraj, J.","Morawiec, Z.","Skorski, T.","Blasiak, J."],"bibdata":{"bibtype":"article","type":"article","title":"STI571 reduces NER activity in BCR/ABL-expressing cells","volume":"654","issn":"0027-5107","doi":"10.1016/j.mrgentox.2008.06.002","abstract":"Nucleotide-excision repair (NER) is the most versatile mechanism of DNA repair, recognizing and dealing with a variety of helix-distorting lesions, such as the UV-induced photoproducts cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) photoproducts. We investigated the influence of an anticancer drug, STI571, on the efficacy of NER in removing UV-induced DNA damage. STI571 is used mostly in the treatment of chronic myeloid leukemia and inhibits activity of the BCR/ABL oncogenic tyrosine kinase, which is a hallmark of this disease. NER activity was examined in the BCR/ABL-expressing cell lines K562 and BV173 of myeloid and lymphoid origin, respectively, as well as in CCRF-CEM cells, which do not express BCR/ABL. A murine myeloid parental 32D cell line and its counterpart transfected with the BCR/ABL gene were also tested. NER activity was assessed in the cell extracts by use of an UV-irradiated plasmid as a substrate and by a modified single-cell gel electrophoresis (comet) assay on UV-treated nucleoids. Additionally, quantitative PCR was performed to evaluate the efficacy of the removal of UV-induced lesions from the p53 gene by intact cells. Results obtained from these experiments indicate that STI571 decreases the efficacy of NER in leukemic cells expressing BCR/ABL. Therefore, STI571 may overcome the drug resistance associated with increased DNA repair in BCR/ABL-positive leukemias.","language":"eng","number":"2","journal":"Mutation Research","author":[{"propositions":[],"lastnames":["Sliwinski"],"firstnames":["Tomasz"],"suffixes":[]},{"propositions":[],"lastnames":["Czechowska"],"firstnames":["Agnieszka"],"suffixes":[]},{"propositions":[],"lastnames":["Szemraj"],"firstnames":["Janusz"],"suffixes":[]},{"propositions":[],"lastnames":["Morawiec"],"firstnames":["Zbigniew"],"suffixes":[]},{"propositions":[],"lastnames":["Skorski"],"firstnames":["Tomasz"],"suffixes":[]},{"propositions":[],"lastnames":["Blasiak"],"firstnames":["Janusz"],"suffixes":[]}],"month":"July","year":"2008","pmid":"18602021","keywords":"Animals, Benzamides, Cell Line, Tumor, Cell Survival, DNA Repair, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Piperazines, Polymerase Chain Reaction, Pyrimidines, comet assay","pages":"162–167","bibtex":"@article{sliwinski_sti571_2008,\n\ttitle = {{STI571} reduces {NER} activity in {BCR}/{ABL}-expressing cells},\n\tvolume = {654},\n\tissn = {0027-5107},\n\tdoi = {10.1016/j.mrgentox.2008.06.002},\n\tabstract = {Nucleotide-excision repair (NER) is the most versatile mechanism of DNA repair, recognizing and dealing with a variety of helix-distorting lesions, such as the UV-induced photoproducts cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) photoproducts. We investigated the influence of an anticancer drug, STI571, on the efficacy of NER in removing UV-induced DNA damage. STI571 is used mostly in the treatment of chronic myeloid leukemia and inhibits activity of the BCR/ABL oncogenic tyrosine kinase, which is a hallmark of this disease. NER activity was examined in the BCR/ABL-expressing cell lines K562 and BV173 of myeloid and lymphoid origin, respectively, as well as in CCRF-CEM cells, which do not express BCR/ABL. A murine myeloid parental 32D cell line and its counterpart transfected with the BCR/ABL gene were also tested. NER activity was assessed in the cell extracts by use of an UV-irradiated plasmid as a substrate and by a modified single-cell gel electrophoresis (comet) assay on UV-treated nucleoids. Additionally, quantitative PCR was performed to evaluate the efficacy of the removal of UV-induced lesions from the p53 gene by intact cells. Results obtained from these experiments indicate that STI571 decreases the efficacy of NER in leukemic cells expressing BCR/ABL. Therefore, STI571 may overcome the drug resistance associated with increased DNA repair in BCR/ABL-positive leukemias.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Mutation Research},\n\tauthor = {Sliwinski, Tomasz and Czechowska, Agnieszka and Szemraj, Janusz and Morawiec, Zbigniew and Skorski, Tomasz and Blasiak, Janusz},\n\tmonth = jul,\n\tyear = {2008},\n\tpmid = {18602021},\n\tkeywords = {Animals, Benzamides, Cell Line, Tumor, Cell Survival, DNA Repair, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Piperazines, Polymerase Chain Reaction, Pyrimidines, comet assay},\n\tpages = {162--167},\n}\n\n","author_short":["Sliwinski, T.","Czechowska, A.","Szemraj, J.","Morawiec, Z.","Skorski, T.","Blasiak, J."],"key":"sliwinski_sti571_2008","id":"sliwinski_sti571_2008","bibbaseid":"sliwinski-czechowska-szemraj-morawiec-skorski-blasiak-sti571reducesneractivityinbcrablexpressingcells-2008","role":"author","urls":{},"keyword":["Animals","Benzamides","Cell Line","Tumor","Cell Survival","DNA Repair","Humans","Imatinib Mesylate","Leukemia","Myelogenous","Chronic","BCR-ABL Positive","Mice","Piperazines","Polymerase Chain Reaction","Pyrimidines","comet assay"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/tplas","dataSources":["YLgywGcXWx96vKKaB"],"keywords":["animals","benzamides","cell line","tumor","cell survival","dna repair","humans","imatinib mesylate","leukemia","myelogenous","chronic","bcr-abl positive","mice","piperazines","polymerase chain reaction","pyrimidines","comet assay"],"search_terms":["sti571","reduces","ner","activity","bcr","abl","expressing","cells","sliwinski","czechowska","szemraj","morawiec","skorski","blasiak"],"title":"STI571 reduces NER activity in BCR/ABL-expressing cells","year":2008}